Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Consensus Rating of “Buy” by Analysts

Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) have received a consensus recommendation of “Buy” from the eight ratings firms that are covering the stock, MarketBeat.com reports. Six research analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month price target among analysts that have covered the stock in the last year is $11.67.

A number of brokerages have issued reports on ACRS. BTIG Research raised shares of Aclaris Therapeutics from a “neutral” rating to a “buy” rating and set a $8.00 price objective on the stock in a research note on Tuesday, November 19th. Jefferies Financial Group raised shares of Aclaris Therapeutics from a “hold” rating to a “buy” rating and lifted their price objective for the company from $2.00 to $7.00 in a research report on Tuesday, November 19th. Scotiabank started coverage on shares of Aclaris Therapeutics in a report on Friday. They set a “sector outperform” rating and a $15.00 target price for the company. StockNews.com cut shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, February 8th. Finally, HC Wainwright upgraded shares of Aclaris Therapeutics from a “neutral” rating to a “buy” rating and set a $20.00 target price for the company in a research report on Monday, December 23rd.

Institutional Investors Weigh In On Aclaris Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. Assenagon Asset Management S.A. raised its stake in Aclaris Therapeutics by 113.9% in the fourth quarter. Assenagon Asset Management S.A. now owns 397,362 shares of the biotechnology company’s stock valued at $985,000 after purchasing an additional 211,585 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its holdings in shares of Aclaris Therapeutics by 187.6% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 332,406 shares of the biotechnology company’s stock valued at $382,000 after buying an additional 216,826 shares in the last quarter. BML Capital Management LLC boosted its holdings in shares of Aclaris Therapeutics by 9.7% during the 3rd quarter. BML Capital Management LLC now owns 14,250,000 shares of the biotechnology company’s stock valued at $16,388,000 after buying an additional 1,261,866 shares in the last quarter. Geode Capital Management LLC boosted its stake in Aclaris Therapeutics by 9.3% in the 3rd quarter. Geode Capital Management LLC now owns 846,446 shares of the biotechnology company’s stock worth $974,000 after purchasing an additional 72,309 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. bought a new position in Aclaris Therapeutics during the 3rd quarter valued at about $1,053,000. 98.34% of the stock is owned by hedge funds and other institutional investors.

Aclaris Therapeutics Price Performance

Aclaris Therapeutics stock opened at $1.66 on Tuesday. Aclaris Therapeutics has a fifty-two week low of $0.95 and a fifty-two week high of $5.17. The firm has a market cap of $179.15 million, a price-to-earnings ratio of -3.19 and a beta of 0.48. The firm has a fifty day moving average price of $2.33 and a two-hundred day moving average price of $2.19.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.